ArticleJournal of the National Comprehensive Cancer Network : JNCCN2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Evaluating the prognostic value of body mass index in diffuse large B-cell lymphoma: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.Frontiers in oncology · 2025Article
- Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system.PloS one · 2025Article
- Body mass index and survival of patients with lymphoma.Leukemia & lymphoma · 2021Article
- Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.BMC cancer · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 1 country.
Zheng ZhouFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Alfred W RademakerFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Leo I GordonFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Ann S LaCasceFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Allison Crosby-ThompsonFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Ann VanderplasFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Gregory A AbelFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Maria A RodriguezFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Auayporn NademaneeFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Mark S KaminskiFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Myron S CzuczmanFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Michael M MillensonFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Andrew D ZelenetzFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Joyce NilandFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Jonathan W FriedbergFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Jane N WinterFrom Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
Northwestern University · USCity Of Hope National Medical Center · USDana-Farber Cancer Institute · USFox Chase Cancer Center · USMemorial Sloan Kettering Cancer Center · USMichigan Center for Translational Pathology · USRoswell Park Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Rochester · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MCLINICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA079447 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LICHT, JONATHAN D. · 1999 to 2013
$3.1MNCI NIH HHS P30 CA008748NCI NIH HHS T32 CA079447
Abstract
backgroundThe impact of patient body habitus and sex on outcomes in diffuse large B-cell lymphoma (DLBCL) remains controversial. We investigated the impact of body mass index (BMI), body surface area (BSA), age, and sex on clinical outcomes in patients with DLBCL treated in the rituximab era. PATIENTS AND
methodsPatients with de novo DLBCL (n=1,386) diagnosed between June 2000 and December 2010 treated with rituximab-containing chemotherapy were identified from the NCCN Oncology Outcomes Database for Non-Hodgkin's Lymphoma. Progression-free survival (PFS) and overall survival (OS) at 3 years were analyzed based on sex, age, and baseline BMI/BSA.
resultsHigh BMI was associated with a lower risk of disease progression or death than low or normal BMI, whereas male sex was associated with poor clinical outcomes, especially among elderly patients (age >60 years). Compared with elderly women, elderly men experienced worse PFS (3-year hazard ratio [HR], 1.5) and OS (3-year HR, 1.6), but these differences diminished with increases in BMI and BSA. In multivariable analysis, normal BMI compared with high BMI was independently associated with poor outcomes (3-year PFS HR, 1.5; OS HR, 1.6) after adjusting for sex. Notably, only 13% of elderly men had BMI less than 25 kg/m
Indexed as
Antineoplastic AgentsBody Mass IndexCohort StudiesFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProspective StudiesRituximabTreatment OutcomeAntineoplastic AgentsRituximab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.